<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04711603</url>
  </required_header>
  <id_info>
    <org_study_id>MR13A9-5</org_study_id>
    <nct_id>NCT04711603</nct_id>
  </id_info>
  <brief_title>A Phase III Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.</brief_title>
  <official_title>A Phase III Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kissei Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kissei Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double-blind, Placebo-controlled study to confirm the superiority of MR13A9 to placebo, and&#xD;
      followed by extension, open-label treatment to confirm long-term safety of MA13A9 in&#xD;
      hemodialysis patients with pruritus.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 16, 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Numerical Rating Scale (NRS) score of itch</measure>
    <time_frame>Up to 58 weeks</time_frame>
    <description>Change from baseline in average NRS score of itch</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in itching scores of Shiratori severity criteria</measure>
    <time_frame>Up to 58 weeks</time_frame>
    <description>Change from baseline in average itching scores of Shiratori severity criteria</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">172</enrollment>
  <condition>Uremic Pruritus</condition>
  <arm_group>
    <arm_group_label>MR13A9/MR13A9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are administered MR13A9 for 6 weeks (double-blind period), followed by MR13A9 for 52 weeks (open-label period).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/MR13A9</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients are administered Placebo for 6 weeks (double-blind period), followed by MR13A9 for 52 weeks (open-label period).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MR13A9</intervention_name>
    <description>Intravenous administration</description>
    <arm_group_label>MR13A9/MR13A9</arm_group_label>
    <arm_group_label>Placebo/MR13A9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous administration</description>
    <arm_group_label>Placebo/MR13A9</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with Chronic Kidney Disease (CKD) has been on hemodialysis 3 times per week&#xD;
&#xD;
          -  Patient receiving treatment for itch&#xD;
&#xD;
          -  Patient has a baseline NRS score &gt; 4&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has pruritus cause other than CKD or its complications&#xD;
&#xD;
          -  Patients has hepatic cirrhosis&#xD;
&#xD;
          -  Patient has a known history of allergic reaction to opiates&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naomi Koshihara</last_name>
    <role>Study Director</role>
    <affiliation>Kissei Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Multiple Locations</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 13, 2021</study_first_submitted>
  <study_first_submitted_qc>January 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2021</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

